The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare Species
Open accessAbstract
Invasive yeast infections represent a major global public health issue, and only few antifungal agents are available. Azoles are one of the classes of antifungals used for treatment of invasive candidiasis. The determination of antifungal susceptibility profiles using standardized methods is important to identify resistant isolates and to uncover the potential emergence of intrinsically resistant species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In multiple population studies over the last two decades, C. albicans is almost uniformly susceptible to fluconazole, the echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to fluconazole is uncommon, with rates generally ranging between 0% and 3%, but averaging less than 1% overall.27,62,102,103,109”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [102]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
The Fungal Holomorph: Mitotic, Meiotic and Pleomorphic Speciation in Fungal Systematics
Reynolds, D. R., & Taylor, J. R. (1993) · Cited by 973
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · cited 1×
“parapsilosis isolates similar to that reported in international surveys (17, 19, 20, 28, 44).”
Resultde Hoog, G. S., & van den Ende, A. H. G. G. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00321.x · Cited by 574
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Self-citationCandidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474 · cited 1×
“accumulation of toxic 14-a-demethylated sterols in the membrane (9).”
BackgroundPopulation-Based Analysis of Invasive Fungal Infections, France, 2001–2010
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., Che, D., & Dromer, F. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.140087 · Cited by 426 · cited 1×
“(iii) Bias related to the isolates analyzed could be a factor, knowing that 22% of the isolates were sent for expert analysis following therapeutic failure and were not part of the epidemiological surveys (2, 45).”
BackgroundSelf-citationSurveillance for control of antimicrobial resistance
Tacconelli, E., Sifakis, F., Harbarth, S., Schrijver, R., van Mourik, M., Voss, A., Sharland, M., Rajendran, N. B., Rodríguez-Baño, J., Bielicki, J., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30485-1 · Cited by 376
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368 · cited 1×
“Centralized data are therefore important for these species to determine their normal susceptibility profiles (10).”
Background
Research works printed but not linked: 1
- 10.1093/0fid/ofy187 · doi:10.1093/0fid/ofy187
Cited by
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“27,62,102,103,109 In many parts of the world, C. glabrata is the second most common cause of IC, particularly affecting older individuals and those with significant underlying immunosuppression.”
BackgroundBretagne, S., Sitbon, K., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Letscher‐Bru, V., Cassaing, S., Millon, L., Morio, F., Gangneux, J., Hasseine, L., et al. (2022) · mBio · doi:10.1128/mbio.00920-22 · Cited by 113
Self-citationBoutin, C.-A., Durocher, F., Beauchemin, S., Ziegler, D., Chakra, C. N. A., & Dufresne, S. F. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae203 · Cited by 79
“In the French study, the MICs to voriconazole and posaconazole were generally low, but posaconazole MIC distribution for S. capitata was slightly higher than voriconazole [27].”
BackgroundNon-Saccharomyces yeasts for beer production: Insights into safety aspects and considerations
Miguel, G. A., Carlsen, S., Arneborg, N., Saerens, S., Laulund, S., & Knudsen, G. M. (2022) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2022.109951 · Cited by 75
Noster, J., Koeppel, M. B., Desnos‐Ollivier, M., Aigner, M., Bader, O., Dichtl, K., Göttig, S., Haas, A., Kurzai, O., Pranada, A. B., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01834-21 · Cited by 33
“All isolates had previously been identified in the respective institutions as M. capitatus/M. clavatus, Blastoschizomyces, or Geotrichum species by different methods, including microscopy, biochemical analysis (Vitek2, API 32C [bioMérieux, Nürtingen, Germany]), or MALDI-TOF MS. February 2022 Volume 66 Issue 2 e01834-2…”
MethodSelf-citationA Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
Astvad, K. M. T., Arıkan-Akdağlı, S., & Arendrup, M. C. (2022) · Journal of Fungi · doi:10.3390/jof8020141 · Cited by 39
“inkin 1 1 1st line Alt (BIIu) n = 10; 2/4 [42], n = 3; (2) [37], n = 2; (1) [50] C.”
InfluentialChanges in fungal taxonomy: mycological rationale and clinical implications
Borman, A. M., & Johnson, E. M. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00099-22 · Cited by 41
Epidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study
Alobaid, K., Ahmad, S., Asadzadeh, M., Mokaddas, E. M., Al‐Sweih, N., Benwan, K. A., Alfouzan, W. A., Al‐Obaid, I., Jeragh, A., Al-Roomi, E., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080673 · Cited by 35
“pelliculosa exhibited reduced susceptibility to fluconazole but were susceptible to caspofungin, which is consistent with data reported in other studies [14,18,34,76,77].”
ResultRodríguez‐Cerdeira, C., Pinto‐Almazán, R., Saunte, D. M. L., Hay, R. J., Szepietowski, J. C., Moreno‐Coutiño, G., Skerlev, M., Prohić, A., & Martínez-Herrera, E. O. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20273 · Cited by 29
Candida haemulonii complex, an emerging threat from tropical regions?
Françoise, U., Desnos‐Ollivier, M., Govic, Y. L., Sitbon, K., Valentino, R., Peugny, S., Chouaki, T., Mazars, E., Paugam, A., Nicolas, M., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011453 · Cited by 26
Self-citationRamos, L. S., Barbosa, P. F., Lorentino, C. M. A., Lima, J. C., Braga, A. L., Lima, R., Giovanini, L., Casemiro, A. L., Siqueira, N. L. M., da Costa, S. C., et al. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100354 · Cited by 33
Fungal Infections Caused by Kazachstania spp., Strasbourg, France, 2007–2020
Kaeuffer, C., Baldacini, M., Ruge, T., Ruch, Y., Zhu, Y.-J., Cian, M. D., Philouze, G., Bachellier, P., Denis, J., Lefèbvre, N., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2801.211543 · Cited by 19
“bovina isolates showed fluconazole MICs to range from 2 to 8 μg/mL (12).”
BackgroundCaicedo-Bejarano, L. D., Osorio-Vanegas, L. S., Ramírez-Castrillón, M., Castillo, J. E., Martínez-Garay, C. A., & Chávez, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043428 · Cited by 20
“They are susceptible to acquiring resistance to medical antifungals, such as fluconazole, which is the most widely used agent in the clinic as primary treatment [13], and triazole fungicides, which are frequently used in agriculture [14], while some of them have intrinsic resistance, such as the species Candida krusei…”
BackgroundCandida haemulonii Species Complex: A Mini-review
Francisco, E. C., de Jong, A. W., & Colombo, A. L. (2023) · Mycopathologia · doi:10.1007/s11046-023-00748-8 · Cited by 19
Paccoud, O., Desnos‐Ollivier, M., Persat, F., Demar, M., Sitbon, K., Bellanger, A., Bonhomme, J., Bonnal, C., Botterel, F., Bougnoux, M., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.031 · Cited by 18
Self-citationWang, Q., Cai, X., Li, Y., Zhao, J., Liu, Z., Jiang, Y., Ling, M., Li, Y., Pan, S., Ai, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1006375 · Cited by 20
Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens
Górzyńska, A., Kondracka, K., Korzeniowska‐Kowal, A., & Nawrot, U. (2024) · Pathogens · doi:10.3390/pathogens13030248 · Cited by 16
“Similarly, for micafungin, the MIC range obtained in this study was slightly lower than the values reported by Desnos-Ollivier et al. [26] (Tables 1 and 2).”
BackgroundResultInfluentialPaccoud, O., Desnos‐Ollivier, M., Cassaing, S., Sitbon, K., Alanio, A., Bellanger, A., Bonnal, C., Bonhomme, J., Botterel, F., Bougnoux, M., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad658 · Cited by 16
Self-citationKraft, L., Ribeiro, V. S. T., Petroski, L. P., Herai, R. H., Peronni, K. C., Figueiredo, D. L. A., Motta, F. D. A., & Tuon, F. F. (2023) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202365012 · Cited by 9
Eichenberger, E. M., Satola, S. W., Neujahr, D. C., Fowler, V. G., Gupta, D. M., Ford, M. L., & Pouch, S. M. (2023) · Clinical Transplantation · doi:10.1111/ctr.15038 · Cited by 8
Efficacy of rezafungin in a case of Candida spondylodiskitis
Lahouati, M., Tinévez, C., Gabriel, F., Xuereb, F., Lefranc, M., & Dauchy, F. (2024) · Journal of Bone and Joint Infection · doi:10.5194/jbji-9-213-2024 · Cited by 9
McHugh, J., Bayless, D. R., Ranganath, N., Stevens, R. W., Kind, D. R., Wengenack, N. L., & Shah, A. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01057-24 · Cited by 10
Epidemiology and antifungal susceptibilities of rare yeast infections in a tertiary care center
Yavuz, B., Turhan, Ö., Özyurt, Ö. K., Çetinkaya, Ö., Ayaz, Ç. M., Özhak, B., & Mamıkoğlu, L. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04016-1 · Cited by 8
“In the literature, similar to the results of this study, intrinsic resistance to echinocandins and increased resistance to some azoles have been reported for M. clavatus [30, 34, 35].”
Verma, S., Tilak, R., Singh, G., Singh, S., Kumari, A., Rudramurthy, S. M., Spruijtenburg, B., Meis, J. F. G. M., de Groot, T., Meijer, E. F. J., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf420 · Cited by 4
Moreau, J., Noël, T., Point, K., Tewes, F., Deroche, L., Clarhaut, J. A., Fitton‐Ouhabi, V., Cateau, E., Marchand, S., Buyck, J. M., et al. (2024) · Mycoses · doi:10.1111/myc.13704 · Cited by 3
Draft Genome Sequence of the Fluconazole-Resistant Candida palmioleophila Clinical Isolate CBS 18098
Lavergne, R., Barbier, P., Mobuchon, L., Banerjee, A., Prasad, R., & Morio, F. (2022) · Mycopathologia · doi:10.1007/s11046-022-00682-1 · Cited by 3
“Due to a poor in vitro susceptibility to fluconazole [3], its identification is clinically relevant but has been shown to be challenging using conventional methods due to frequent misidentifications [3, 7].”
BackgroundTrichosporon and Antifungal Resistance: Current Knowledge and Gaps
Miranda, I. L., Peres, N. T. A., Bastos, R. W., Rossato, L. L., Morio, F., & Santos, D. A. (2025) · Mycopathologia · doi:10.1007/s11046-025-00969-z · Cited by 5
Belgacem, S., Chebil, W., Salem, S. B., Babba, O., Mastouri, M., & Babba, H. (2024) · Medical Mycology · doi:10.1093/mmy/myae070 · Cited by 3
Alexidine as a Potent Antifungal Agent Against Candida HemeuloniiSensu Stricto
Pimentel, L. R., Lucini, F., da Silva, G. A., Simionatto, S., & Rossato, L. L. (2025) · ACS Omega · doi:10.1021/acsomega.4c11382 · Cited by 2
Clinical Manifestations of Emerging Trichosporon spp. Infections, France
Desnos‐Ollivier, M., Alanio, A., Gits‐Muselli, M., Sitbon, K., Bertho, A., Sturny-Leclère, A., Guémas, E., Poirier, P., Bonnal, C., Bougnoux, M., et al. (2026) · Emerging infectious diseases · doi:10.3201/eid3201.250504 · Cited by 2
“We confirmed that no matter the species or geno - types, voriconazole is the most effective antimicrobial drug in vitro against isolates belonging to the Tricho-sporonaceae family ( 17 , 20 ).”
Self-citationDufresne, S. F., Bergeron, J., Beauchemin, S., Chakra, C. N. A., Vadnais, B., Bouchard, P., Labbé, A., & Laverdière, M. (2023) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0027 · Cited by 4
Repurposing tafenoquine as a potent antifungal agent against Candida haemulonii sensu stricto
Pimentel, L. R., Lucini, F., da Silva, G. A., Simionatto, S., & Rossato, L. L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf054 · Cited by 3
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Candida lusitaniae from Commensal to Opportunistic: A Growing Clinical Concern
Rojas, O. C., & González, G. M. (2025) · Infectious diseases · doi:10.5772/intechopen.1012969 · Cited by 2
Lass‐Flörl, C., Steixner, S. J. M., Bauer, A., Meis, J. F. G. M., Colombo, A. L., Cornely, O. A., Chakrabarti, A., Hagen, F., dos Santos, A. R., Seyedmousavi, S., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00263-26 · Cited by 1
“For instance, in C. parapsilosis , FKS1 mutations can occur in addition to the natural P660A polymorphism, moving MICs from an intrinsically elevated but still treatable WT range into a frankly resistant range; these isolates are NWT and often associated with clinical failure (14, 15).”
InfluentialClinical Microbiology in 2021: My Favorite Studies about Everything Except My Least Favorite Virus
Pettengill, M. A. (2022) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2022.04.003 · Cited by 1
“summarizing azole AST for over 9,000 yeast isolates representing 40 clinically relevant species [15].”
BackgroundMechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Candida , Cryptococcus , and Other Yeasts of Medical Importance
Borman, A. M., & Johnson, E. M. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0121 · Cited by 1
Candida , Cryptococcus , and Other Yeasts of Medical Importance
Borman, A. M., & Johnson, E. M. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0121 · Cited by 2
Qiu, H., Du, H., Li, X., Wang, X., Li, Y., Bilal, H., & Xu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845780
Boglione‐Kerrien, C., Lemaitre, F., Gautier‐Veyret, E., Baklouti, S., Lesne-Hulin, A., Cornet, M., Botterel, F., Morçet, J., Bot, A. L., Verdier, M., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag231
McPherson, A. Z., Miller, M. A., Rytlewski, K., Bacon, S. D., & Frappa, K. E. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261457479
Samarelli, R., Pugliese, N., Mendoza‐Roldan, J. A., Miglianti, M., Fagundes‐Moreira, R., Laricchiuta, P., Legrottaglie, M., Danesi, P., Otranto, D., & Giusiano, G. (2026) · Medical Mycology · doi:10.1093/mmy/myag083
“42 , 43 Reduced susceptibility to azoles was particularly evident in several isolates.”
Alby‐Laurent, F., Obadia, T., Gits‐Muselli, M., Bougnoux, M., Brethon, B., Mariani‐Kurkdjian, P., Guitard, J., Botterel, F., Chachaty, É., Sitbon, K., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104177
Self-citation
Metadata
- Authors
- Desnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F.
- Affiliations
- Institut Pasteur, CNRS, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, UMR2000, Paris, France
- Hôpital Necker-Enfants Malades (FR)
- Centre National de la Recherche Scientifique (FR)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2021-05-18
- Volume
- 65
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC8315974
- OpenAlex
- W3147574361
- Cited by
- 44
- References
- 55
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 7 · 2021: 2
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- Funders
- Sante Publique France
- Institut Pasteur
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- azole susceptibility, clinical yeast isolates, invasive candidiasis, antifungal resistance, Candida species, antifungal susceptibility testing
- MeSH terms
- Antifungal Agents, Azoles, Saccharomycetales, France, Microbial Sensitivity Tests, Pichia, Rhodotorula, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.